|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/10 | |
| A61K 31/498 | |||
| A61K 9/16 |
| (11) | Number of the document | 1879553 |
| (13) | Kind of document | T |
| (96) | European patent application number | 06752463.7 |
| Date of filing the European patent application | 2006-05-09 | |
| (97) | Date of publication of the European application | 2008-01-23 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-12 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2006/018019 |
| Date | 2006-05-09 |
| (87) | Number | WO 2006/122165 |
| Date | 2006-11-16 |
| (30) | Number | Date | Country code |
| 679771 P | 2005-05-10 | US |
| (72) |
HUGHES, Patric, M., US
BURKE, James, A., US
CHANG-LIN, Joan-En, US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES |
| OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES |